logo

AJANTPHARM vs SANOFI: Stock Comparison

AJANTA PHARMA vs SANOFI INDIAUpdated 22 Oct 26, 4:08 PM ISTNSE & company filings

AJANTA PHARMA is the larger company by market capitalisation. AJANTA PHARMA shows faster revenue growth and a higher net margin, while SANOFI INDIA shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

AJANTPHARM leads 5; SANOFI leads 5 of 13

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

AJANTPHARMSANOFI

Valuation lens

What price are you paying?

Market CapContext only
₹40,987 Cr
₹6,529 Cr
P/E RatioSANOFI has the lower reading
36.11x
0x ✓
P/B RatioSANOFI has the lower reading
9.05x
0x ✓
EPSAJANTPHARM has the higher reading
₹90.79 ✓
₹39.64
Book ValueContext only
₹362.35
₹325.31
Dividend YieldSANOFI has the higher reading
1.94%
4.36% ✓

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
AJANTPHARM is the larger company
₹40,987 Cr vs ₹6,529 Cr
P/E Ratio
SANOFI has a lower P/E
0x vs 36.11x
P/B Ratio
SANOFI has a lower P/B
0x vs 9.05x
EPS
AJANTPHARM has higher earnings per share
₹90.79 vs ₹39.64
Dividend Yield
SANOFI has a higher dividend yield
4.36% vs 1.94%
Revenue Growth (TTM YoY)
AJANTPHARM has faster revenue growth
21.5% vs -11.9%
EPS Growth (TTM YoY)
AJANTPHARM has faster EPS growth
18.6% vs -14.1%
ROE
SANOFI has a higher ROE
41.35% vs 22.42%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricAJANTPHARMSANOFI
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricAJANTPHARMSANOFI
Live Price₹3,270.6₹2,831.1
Day Change0.32%0.13%
Volume58,12315,277
52-Week High₹3,796₹4,898
52-Week Low₹2,382₹2,820.1
Distance from 52W High-13.84%-42.2%

Valuation

MetricAJANTPHARMSANOFI
Market Cap₹40,987 Cr₹6,529 Cr
P/E Ratio36.11x0x
P/B Ratio9.05x0x
EPS₹90.79₹39.64
Book Value₹362.35₹325.31
Dividend Yield1.94%4.36%

Growth

MetricAJANTPHARMSANOFI
Revenue Growth (TTM YoY)21.5%-11.9%
EPS Growth (TTM YoY)18.6%-14.1%
Qtr Sales Growth0%0%
Qtr Profit Growth0%0%

Profitability & Leverage

MetricAJANTPHARMSANOFI
ROE22.42%41.35%
ROCE22.95%64.11%
Net Margin19.38%19.26%
Operating Margin25.46%23.62%
Debt to Equity0x0x

Shareholding

As of Sep 2026 • change vs previous quarter
MetricAJANTPHARMSANOFI
Promoter Holding63.47%▼ 0.01 pp0%
FII Holding7.63%▼ 0.05 pp5.69%▲ 0.05 pp
DII Holding21.94%▲ 0.14 pp19.87%▼ 1.26 pp
Public Holding6.96%▼ 0.07 pp14.04%▲ 1.21 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: AJANTA PHARMA and SANOFI INDIA.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.